REGN - MCAP CO - Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (REGN) possesses a pronounced defensive profile, demonstrating resilience to market volatility and an absence of seasonal downturns. A management team with an impeccable reputation in R&D has established a foundation for shareholder trust. This daily price chart, with a market capitalization of 79.97, complements the overall picture of the company's operations. Revenue is generated through the sale of unique biologics for the treatment of asthma, ophthalmological pathologies, and oncology.

Market capitalization captures the final balance of supply and demand, determining the current value of all issuer assets through the lens of macroeconomic factors and interest rates. An analysis of the total market value of the business allows for an assessment of the resilience of Regeneron Pharmaceuticals (REGN), whose model of colossal R&D expenditures is offset by high scalability and superprofits from the sale of innovative biologics.